CA-AMAZENTIS
27.7.2020 15:07:04 CEST | Business Wire | Press release
Pioneering life sciences company, Amazentis , today announces new clinical findings and the commercial launch of Timeline Cellular Nutrition in the United States. After a decade of research by leading scientists and medical doctors, Timeline Nutrition is the first brand to offer Mitopure™, a highly pure form of Urolithin A proven to help counter age-associated cellular decline and improve muscular strength.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005447/en/
- A randomized, double-blind, placebo-controlled clinical trial (NCT03464500 ) in healthy middle-aged participants (40 to 65 years old) showed that 4 months of daily consumption of 500mg Mitopure™ (highly pure Urolithin A) led to a significant improvement in leg muscle strength.
- A separate randomized clinical trial (NCT04160312 ) conducted in healthy adults (18-80 years old) in the USA compared Urolithin A levels following consumption of Mitopure™ and pomegranate juice. It showed that 500mg of Mitopure™ delivers greater than 6X more Urolithin A compared to 8oz (240ml) of 100% pomegranate juice.
- Amazentis is launching the first product containing clinically proven Mitopure™ exclusively direct-to-consumer through the Timeline Nutrition website.
Many people begin to experience a loss in muscle strength starting in their 40s due to age-associated declines in cellular bioenergetics and mitochondrial function. Timeline is formulated with Mitopure™, a proprietary ingredient and highly pure form of Urolithin A. This bioactive is produced by the gut microbiome in only a limited portion of the population. Mitopure™ is the only compound shown to increase muscle function by activating the selective recycling of damaged mitochondria (the powerhouse of the cell) via an essential anti-aging process known as mitophagy.
“For the first time we have now shown that consuming Mitopure™ on a regular basis for 4 months triggers meaningful physiological changes in the body and significantly improves leg muscle strength” says Amazentis Chairman & Co-Founder, Patrick Aebischer, MD “this is a breakthrough in the translation of science-backed nutrition targeting muscle and healthy aging.”
Timeline is particularly effective because precisely calibrated doses of Mitopure™ deliver Urolithin A directly and activate mitophagy within the body—regardless of your diet or microbiome. This new clinical data showed that only 12% of participants had detectable levels of Urolithin A entering the study. Overall, participants showed a greater than 6-fold improvement in Urolithin A levels over 24 hours after consuming 500mg of Mitopure™ when compared to 8oz (240mL) of 100% pomegranate juice.
“At Amazentis, we’re dedicated to developing the next generation of nutrition products targeting cellular health and mitochondrial function. Now, more than ever, consumers appreciate the importance of staying healthy and maintaining muscle function. Timeline Nutrition brings together cutting-edge science with a great tasting product,” says Amazentis CEO and Co-Founder, Chris Rinsch, PhD.
Timeline’s first product comes in the form of a delicious Berry & Pomegranate flavored powder that can be mixed in with your daily smoothie, yogurt, and other breakfast favorites. Timeline is exclusively available for purchase online for consumers in the United States starting at $3.33 per day for a four-month supply. Visit www.timelinenutrition.com for more information.
* 500mg of Mitopure™ have been shown to (1) induce gene expression related to mitochondrial function and metabolism and (2) increase the strength of the hamstring leg muscle in measures of knee extension and flexion in overweight 40 to 65 year olds. Data from two randomized double-blind placebo-controlled human clinical trials.
About Timeline
Timeline Nutrition is the first brand to offer Mitopure™, a highly pure form of Urolithin A. This novel nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of nutrition that is backed by cutting edge science. As scientists, we know that physical decline from aging can’t be stopped. However, through its groundbreaking research, Timeline is committed to developing products designed to help reduce the impact of time on health. For more information, please visit www.timelinenutrition.com
.
About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals such as Nature Medicine
(doi:10.1038/nm.4132) and Nature Metabolism
(doi: 10.1038/s42255-019-0073-4). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular decline. For more information on Amazentis, please visit www.amazentis.com
.
Related Links
https://www.timelinenutrition.com
https://www.mitopure.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005447/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 20261.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resis
EMVCo Requests Feedback on Framework for Secure, Interoperable and Scalable Card-Based Agentic Payments1.9.2026 11:00:00 CEST | Press release
EMVCo – the technical body that creates and manages EMV® Specifications and programmes – has released a draft framework to help promote secure, interoperable and scalable card-based agentic payments. The framework provides a foundation for further industry engagement and potential specification development, with all interested stakeholders encouraged to provide their feedback on EMV® Agentic Payments – Framework for Specificationsby Wednesday 30 September. A key focus across the agentic commerce ecosystem is how to establish intent and determine that a consumer delegated authority to an AI agent to make a purchase on their behalf. Following industry input, EMVCo has focused on card-based agentic payment scenarios where intent needs to be managed over time, such as recurring purchases, cumulative budgets and post-transaction activities. These scenarios may require access to a shared intent ‘state’ that persists across multiple participants and their interactions. EMVCo has identified an
ChargePoint Accelerates European Growth Strategy with Appointment of John Saffrett as EVP and Managing Director, Europe1.9.2026 11:00:00 CEST | Press release
Saffrett brings more than 25 years of leadership experience in global mobility, fleet management, and digital transformationAppointment signals ChargePoint's commitment to accelerating European growth as the company targets increasing its European market and revenue share ChargePoint (NYSE: CHPT), a global leader in intelligent electrification and e-mobility, today announced the appointment of John Saffrett as Executive Vice President and Managing Director, Europe. In this role, Saffrett will be responsible for driving ChargePoint's growth strategy across European markets, overseeing sales, customer relationships, partnerships, and market expansion across the continent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901888806/en/ ChargePoint's EVP and Managing Director John Saffrett He has served as a member of the company’s Advisory Council since March 2026 and is a seasoned global mobility executive with more than 25 ye
Club Vita Launches German VitaCurves Model as Pension Risk Transfer Market Gathers Momentum1.9.2026 10:00:00 CEST | Press release
Address-based longevity model expands Club Vita's global suite of analytics to cover the UK, US, Canada, Netherlands and Germany Club Vita, an international leader in longevity data analytics, has launched a German calibration of its popular address-based longevity model, VitaCurves, further expanding its international footprint and supporting the growing pension risk transfer (PRT) market in Germany. The launch marks another milestone in Club Vita's international expansion and extends its suite of address-based mortality models, which already provides mortality insights in the UK, United States, Canada and the Netherlands. The German VitaCurvesDEU model is already being used by a leading insurer, helping to provide a more granular understanding of longevity risk across pension and insurance portfolios. VitaCurves uses granular location-based and socio-economic data to identify differences in mortality patterns between sub-populations, enabling insurers, pension funds and other stakeho
JEOL: Launch of the New Benchtop Scanning Electron Microscope “JCM-7000Plus NeoScope™”1.9.2026 09:30:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the benchtop scanning electron microscope (SEM) “JCM-7000Plus” and will begin sales on September 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825564112/en/ JCM-7000Plus NeoScope™ [Development Background] Benchtop scanning electron microscopes are increasingly used in fields including electrical and electronics, automotive and machinery, steel and metals, chemical and pharmaceuticals. They are utilized not only in research and development but also in manufacturing-related applications, such as quality control and product inspection. In addition, they are adopted in educational settings at middle and high schools as well as universities. Given these diverse applications, there is growing demand for improved operational efficiency, simpler and more automated operation, and enhanced observation, analysis, and measurement performance. To meet these needs, we have e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom